TEA Changes, GRASE Basics Central To CHPA Monograph Comments
This article was originally published in The Tan Sheet
Executive Summary
CHPA suggests accelerating the introduction of additional monograph ingredients while hewing to the agency’s existing OTC Drug Review. The group also says “if FDA returns to the origins of the OTC Drug Review and examines the bases for its early success, the remaining monographs can be completed and updated.”
You may also be interested in...
J&J Suggests Targeting OTC Monograph With Public-Private Initiative
An FDA guidance provides the framework for J&J consumer business executives’ suggestions to improve the OTC drug review. A public-private partnership “is key to developing and delivering a comprehensive solution,” says Lynne Szczepaniak, regulatory affairs VP at J&J’s McNeil Consumer Healthcare subsidiary.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.